included in the initial unit sales were 5,000,000 units that were issued upon conversion of $ 5,000,000 of ekso bionics ' senior subordinated secured convertible notes ( the “ 2013 bridge notes ” ) issued to accredited investors in november 2013. in addition , investors in the 2013 bridge notes received warrants to purchase 2,500,000 shares of common stock at an exercise price of $ 1.00 per share for a term of three years ( the “ bridge warrants ” ) upon the closing of the merger and the ppo . the placement agent for the ppo and its sub-agents were paid an aggregate commission of $ 3,030,000 and were issued warrants to purchase an aggregate of 3,030,000 shares of our common stock at $ 1.00 per share with a five year term . 41 in february 2014 , an additional 779,768 shares of our common stock were issued to pre-merger shareholders of pn med group inc. pursuant to a provision in the merger agreement requiring us to issue a number of shares such that the aggregate ownership of the pre-merger shareholders ( not including any shares of common stock purchased by them in the ppo ) remained approximately 6.8 % of the outstanding common stock of the company . in november 2014 , the company consummated an offer to amend and exercise ( the “ offer to amend and exercise ” ) its ppo warrants at a temporarily reduced exercise price . pursuant to the offer to amend and exercise , an aggregate of 22,755,500 ppo warrants were exercised by their holders at an amended exercise price of $ 1.00 per share . these warrants contained “ weighted average ” anti-dilution protection in the event that we issued common stock or securities convertible into or exercisable for shares of common stock at a price lower than the subject warrant 's exercise price , subject to certain customary exceptions , as well as customary provisions for adjustment in the event of stock splits , subdivision or combination , mergers , etc . the anti-dilution protection feature required the company to record the underlying securities as a liability and to adjust their respective values to market at each reporting period . as part of the offer to amend and exercise , the company sought and received approval to amend the warrants to remove the price-based anti-dilution provision . on december 1 , 2015 , the company through its wholly owned subsidiary , ekso bionics , acquired the mechanical balance and support arms technologies of equipois , llc , including the rights to the zerog® and x-ar® products . the initial purchase price for the acquired assets was 781,250 shares of the company 's common stock . the company also agreed to issue additional shares of common stock based upon the achievement of certain post closing performance criteria . on december 23 , 2015 , the company entered into an agreement to sell 15,000 shares of series a preferred stock , par value $ 0.001 ( “ preferred shares ” ) and warrants to purchase 14,851,486 shares of the company 's common stock at an exercise price of $ 1.25 per share for a term of five years ( each , a “ warrant ” and collectively , the “ warrants ” ) , to certain institutional investors in a registered direct offering at a purchase price of $ 1,000 for each preferred share and related warrants for aggregate proceeds of $ 15,000,000. see note 13 on our consolidated financial statements under the caption , “ capitalization and equity structure – convertible preferred stock ” and “ capitalization and equity structure – warrants – 2015 warrants ” for a description of the preferred shares and warrants . business we design , develop and sell exoskeletons that have applications in healthcare , industrial , military , and consumer markets . our exoskeletons systems are worn over the user 's clothing and augment human strength , endurance and mobility . these systems serve multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities . we or our partners have sold , rented or leased devices that ( a ) enable individuals with neurological conditions affecting gait ( e.g . , spinal cord injury or stroke ) to rehabilitate and to walk again ; ( b ) allow industrial workers to perform heavy duty work for extended periods ; and ( c ) permit soldiers to carry heavy loads for long distances while mitigating lower back , knee , and ankle injuries . our long-term goal is to have one million persons stand and walk in ekso exoskeletons by february 2022. the first step to achieving that goal is for us to focus on selling our medical exoskeletons to rehabilitation centers and hospitals in the united states and europe . ekso bionics began that effort with the february 2012 sale of ekso , an exoskeleton for complete spinal cord injuries ( “ sci ” ) . we have expanded that effort with the launch of our variable assist software and the announcement of our newest hardware platform , ekso gt . the variable assist software enables users with any amount of lower extremity strength to contribute their own power for either leg to achieve self-initiated walking . the ekso gt builds on the experience of the ekso and incorporates variable assist , allowing us to expand our sales and marketing efforts beyond sci-focused centers to centers supporting stroke and related neurological patients . in the u.s. there are about 5.9 million stroke and sci rehabilitation sessions conducted on about 680,000 stroke and sci patients at 16,900 facilities . globally , there are an estimated 50,000 rehabilitation facilities . in parallel to the development and early commercialization of medical exoskeletons , we have begun to work on the commercialization of exoskeletons for able-bodied users , specifically for industrial and construction applications . story_separator_special_tag general and administrative expenses decreased $ 0.4 million , or 5 % , during the year ended december 31 , 2015 compared to the year ended december 31 , 2014 , partially due to the absence in 2015 of a one-time bonus pay out of $ 0.3 million and professional services fees both associated with the 2014 private placement offering . general and administrative expense in 2015 included an increase in non-cash stock-based compensation of $ 0.1 million . other income ( expense ) , net other income ( expense ) , net reflects a change of $ 19.0 million , or 112 % , during the year ended december 31 , 2015 compared to the year ended december 31 , 2014. the 2015 results reflect the effect of the december 2015 issuance of warrants to purchase 14.9 million shares of common stock in conjunction with our issuance of 15,000 shares of series a convertible preferred stock . the warrants were initially valued at $ 11.7 million and a warrant liability was recorded . due to a decrease in our per share stock price from the transaction date to december 31 , 2015 , the warrant liability was reduced by $ 2.5 million , resulting in a non-cash gain . the results for 2014 reflect the issuance of warrants during the merger and subsequent ppo , that due to an anti-dilutive featue of the warrants then in effect , resulted in a non-cash charge of $ 16.5 million . see note 13 on our consolidated financial statements under the caption , “ capitalization and equity structure – warrants ” for a description of the warrants , including the method and inputs used to estimate their fair value . preferred deemed dividend on december 23 , 2015 , the company entered into an agreement to sell 15,000 shares of series a convertible preferred stock and warrants to purchase 14.9 million shares of the company 's common stock , for cash of $ 13.7 million , net of issuance cost , of which $ 0.2 million was paid in 2016. because the preferred shares were in-the-money on the date of issuance , the company recognized a beneficial conversion feature of $ 3.3 million that was recorded as a non-cash preferred deemed dividend . in december 2015 , 1,737 shares of preferred shares were converted into 1,720,003 million shares of common stock resulting in an additional $ 1.4 million non-cash preferred deemed dividend that related to the accretion of the discount associated with the warrants and stock issuance costs . total preferred deemed dividends for the year were $ 4.7 million . see note 13 on our consolidated financial statements under the caption , “ capitalization and equity structure – convertible preferred stock ” for a additional information . 48 comparison of the year ended december 31 , 2014 to the year ended december 31 , 2013 ( dollars in thousands ) : replace_table_token_5_th revenue medical device revenue increased $ 1.3 million , or 81 % , as compared to the year ended december 31 , 2013 due to an increase in recognized revenue as the number of medical device sales being amortized to revenue more than doubled compared to the same period in the prior year . engineering services revenue increased $ 0.7 million , or 42 % , as compared to the year ended december 31 , 2013 from an overall net increase in revenue generating projects , primarily a result of our work on the u.s. special operations command 's talos project in 2014. gross profit overall , gross profit increased by approximately $ 1.0 million , or 166 % , as compared to the year ended december 31 , 2013. our medical device gross profit increased by $ 0.7 million , or 480 % , due to an increase of 52 units in the field . engineering services gross profit increased by $ 0.2 million , or 57 % , due primarily to a new revenue generating project with the u.s. special operations command . operating expenses sales and marketing expenses increased $ 2.8 million , or 65 % , as compared to the year ended december 31 , 2013 largely from an increase of $ 1.3 million in compensation related costs . in 2013 , compensation costs were kept low pending an inflow of investment capital . in addition , travel costs increased by $ 0.4 million , reflecting greater sales efforts , and stock compensation increased by $ 0.2 million , as a result of grants made during 2014. the fact that the company went public in early 2014 lead to a greater media presence during the year , which caused an increase in marketing related expenses by $ 0.6 million compared to 2013 . 49 research and development expenses increased $ 1.2 million , or 44 % , as compared to the year ended december 31 , 2013 primarily from an increase of $ 0.6 million in compensation related costs . as noted above , compensation costs were kept low in 2013 pending an inflow of investment capital . in addition , head count increased from approximately 13 employees at the end of 2013 to approximately 24 employees at the end of 2014. patent related expenses increased by approximately $ 0.2 million in 2014 compared to 2013. general and administrative expenses increased $ 3.5 million , or 89 % , as compared to the year ended december 31 , 2013 , due primarily to a $ 1.8 million increase in compensation-related costs as compared to the year ended december 31 , 2013. as noted above , compensation costs were kept low in 2013 pending an inflow of investment capital . in addition , we incurred $ 1.6 million in professional services fees primarily related to the merger , public company requirements and investor relations expenses . other income ( expense ) , net total other income ( expense ) , net reflected an increase of $

cash and working capital since the company 's inception , we have incurred recurring net losses and negative cash flows from operations . we have incurred net losses of $ 19.6 million , $ 33.8 million and $ 11.9 million for the years ended december 31 , 2015 , 2014 and 2013 , respectively . in addition , our operating activities have used $ 18.3 million , $ 15.0 million and $ 9.1 million in cash for the years ended december 31 , 2015 , 2014 , and 2013 , respectively . liquidity and capital resources largely as a result of significant research and development activities related to the development of our advanced technology and commercialization of this technology into our medical device business , we have incurred significant operating losses and negative cash flows from operations since inception . we have also recognized significant non-cash losses associated with the revaluation of certain securities , which have also contributed significantly to our accumulated deficit . as of december 31 , 2015 , we had an accumulated deficit of $ 91.4 million . cash on hand at december 31 , 2015 was $ 19.6 million , compared to $ 25.2 million at december 31 , 2014. based upon our current twelve-month average monthly net use of cash of approximately $ 1.5 million and assuming increases in current revenue , offset by incremental net use of cash for increased sales and marketing and research and development , and a potential increase in rental activity from our medical device business , we believe we have sufficient resources to meet our financial obligations into the first quarter of 2017 . 50 our actual capital requirements may vary significantly and will depend on many factors .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash and working capital since the company 's inception , we have incurred recurring net losses and negative cash flows from operations . we have incurred net losses of $ 19.6 million , $ 33.8 million and $ 11.9 million for the years ended december 31 , 2015 , 2014 and 2013 , respectively . in addition , our operating activities have used $ 18.3 million , $ 15.0 million and $ 9.1 million in cash for the years ended december 31 , 2015 , 2014 , and 2013 , respectively . liquidity and capital resources largely as a result of significant research and development activities related to the development of our advanced technology and commercialization of this technology into our medical device business , we have incurred significant operating losses and negative cash flows from operations since inception . we have also recognized significant non-cash losses associated with the revaluation of certain securities , which have also contributed significantly to our accumulated deficit . as of december 31 , 2015 , we had an accumulated deficit of $ 91.4 million . cash on hand at december 31 , 2015 was $ 19.6 million , compared to $ 25.2 million at december 31 , 2014. based upon our current twelve-month average monthly net use of cash of approximately $ 1.5 million and assuming increases in current revenue , offset by incremental net use of cash for increased sales and marketing and research and development , and a potential increase in rental activity from our medical device business , we believe we have sufficient resources to meet our financial obligations into the first quarter of 2017 . 50 our actual capital requirements may vary significantly and will depend on many factors .
```    
 Suspicious Activity Report : included in the initial unit sales were 5,000,000 units that were issued upon conversion of $ 5,000,000 of ekso bionics ' senior subordinated secured convertible notes ( the “ 2013 bridge notes ” ) issued to accredited investors in november 2013. in addition , investors in the 2013 bridge notes received warrants to purchase 2,500,000 shares of common stock at an exercise price of $ 1.00 per share for a term of three years ( the “ bridge warrants ” ) upon the closing of the merger and the ppo . the placement agent for the ppo and its sub-agents were paid an aggregate commission of $ 3,030,000 and were issued warrants to purchase an aggregate of 3,030,000 shares of our common stock at $ 1.00 per share with a five year term . 41 in february 2014 , an additional 779,768 shares of our common stock were issued to pre-merger shareholders of pn med group inc. pursuant to a provision in the merger agreement requiring us to issue a number of shares such that the aggregate ownership of the pre-merger shareholders ( not including any shares of common stock purchased by them in the ppo ) remained approximately 6.8 % of the outstanding common stock of the company . in november 2014 , the company consummated an offer to amend and exercise ( the “ offer to amend and exercise ” ) its ppo warrants at a temporarily reduced exercise price . pursuant to the offer to amend and exercise , an aggregate of 22,755,500 ppo warrants were exercised by their holders at an amended exercise price of $ 1.00 per share . these warrants contained “ weighted average ” anti-dilution protection in the event that we issued common stock or securities convertible into or exercisable for shares of common stock at a price lower than the subject warrant 's exercise price , subject to certain customary exceptions , as well as customary provisions for adjustment in the event of stock splits , subdivision or combination , mergers , etc . the anti-dilution protection feature required the company to record the underlying securities as a liability and to adjust their respective values to market at each reporting period . as part of the offer to amend and exercise , the company sought and received approval to amend the warrants to remove the price-based anti-dilution provision . on december 1 , 2015 , the company through its wholly owned subsidiary , ekso bionics , acquired the mechanical balance and support arms technologies of equipois , llc , including the rights to the zerog® and x-ar® products . the initial purchase price for the acquired assets was 781,250 shares of the company 's common stock . the company also agreed to issue additional shares of common stock based upon the achievement of certain post closing performance criteria . on december 23 , 2015 , the company entered into an agreement to sell 15,000 shares of series a preferred stock , par value $ 0.001 ( “ preferred shares ” ) and warrants to purchase 14,851,486 shares of the company 's common stock at an exercise price of $ 1.25 per share for a term of five years ( each , a “ warrant ” and collectively , the “ warrants ” ) , to certain institutional investors in a registered direct offering at a purchase price of $ 1,000 for each preferred share and related warrants for aggregate proceeds of $ 15,000,000. see note 13 on our consolidated financial statements under the caption , “ capitalization and equity structure – convertible preferred stock ” and “ capitalization and equity structure – warrants – 2015 warrants ” for a description of the preferred shares and warrants . business we design , develop and sell exoskeletons that have applications in healthcare , industrial , military , and consumer markets . our exoskeletons systems are worn over the user 's clothing and augment human strength , endurance and mobility . these systems serve multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities . we or our partners have sold , rented or leased devices that ( a ) enable individuals with neurological conditions affecting gait ( e.g . , spinal cord injury or stroke ) to rehabilitate and to walk again ; ( b ) allow industrial workers to perform heavy duty work for extended periods ; and ( c ) permit soldiers to carry heavy loads for long distances while mitigating lower back , knee , and ankle injuries . our long-term goal is to have one million persons stand and walk in ekso exoskeletons by february 2022. the first step to achieving that goal is for us to focus on selling our medical exoskeletons to rehabilitation centers and hospitals in the united states and europe . ekso bionics began that effort with the february 2012 sale of ekso , an exoskeleton for complete spinal cord injuries ( “ sci ” ) . we have expanded that effort with the launch of our variable assist software and the announcement of our newest hardware platform , ekso gt . the variable assist software enables users with any amount of lower extremity strength to contribute their own power for either leg to achieve self-initiated walking . the ekso gt builds on the experience of the ekso and incorporates variable assist , allowing us to expand our sales and marketing efforts beyond sci-focused centers to centers supporting stroke and related neurological patients . in the u.s. there are about 5.9 million stroke and sci rehabilitation sessions conducted on about 680,000 stroke and sci patients at 16,900 facilities . globally , there are an estimated 50,000 rehabilitation facilities . in parallel to the development and early commercialization of medical exoskeletons , we have begun to work on the commercialization of exoskeletons for able-bodied users , specifically for industrial and construction applications . story_separator_special_tag general and administrative expenses decreased $ 0.4 million , or 5 % , during the year ended december 31 , 2015 compared to the year ended december 31 , 2014 , partially due to the absence in 2015 of a one-time bonus pay out of $ 0.3 million and professional services fees both associated with the 2014 private placement offering . general and administrative expense in 2015 included an increase in non-cash stock-based compensation of $ 0.1 million . other income ( expense ) , net other income ( expense ) , net reflects a change of $ 19.0 million , or 112 % , during the year ended december 31 , 2015 compared to the year ended december 31 , 2014. the 2015 results reflect the effect of the december 2015 issuance of warrants to purchase 14.9 million shares of common stock in conjunction with our issuance of 15,000 shares of series a convertible preferred stock . the warrants were initially valued at $ 11.7 million and a warrant liability was recorded . due to a decrease in our per share stock price from the transaction date to december 31 , 2015 , the warrant liability was reduced by $ 2.5 million , resulting in a non-cash gain . the results for 2014 reflect the issuance of warrants during the merger and subsequent ppo , that due to an anti-dilutive featue of the warrants then in effect , resulted in a non-cash charge of $ 16.5 million . see note 13 on our consolidated financial statements under the caption , “ capitalization and equity structure – warrants ” for a description of the warrants , including the method and inputs used to estimate their fair value . preferred deemed dividend on december 23 , 2015 , the company entered into an agreement to sell 15,000 shares of series a convertible preferred stock and warrants to purchase 14.9 million shares of the company 's common stock , for cash of $ 13.7 million , net of issuance cost , of which $ 0.2 million was paid in 2016. because the preferred shares were in-the-money on the date of issuance , the company recognized a beneficial conversion feature of $ 3.3 million that was recorded as a non-cash preferred deemed dividend . in december 2015 , 1,737 shares of preferred shares were converted into 1,720,003 million shares of common stock resulting in an additional $ 1.4 million non-cash preferred deemed dividend that related to the accretion of the discount associated with the warrants and stock issuance costs . total preferred deemed dividends for the year were $ 4.7 million . see note 13 on our consolidated financial statements under the caption , “ capitalization and equity structure – convertible preferred stock ” for a additional information . 48 comparison of the year ended december 31 , 2014 to the year ended december 31 , 2013 ( dollars in thousands ) : replace_table_token_5_th revenue medical device revenue increased $ 1.3 million , or 81 % , as compared to the year ended december 31 , 2013 due to an increase in recognized revenue as the number of medical device sales being amortized to revenue more than doubled compared to the same period in the prior year . engineering services revenue increased $ 0.7 million , or 42 % , as compared to the year ended december 31 , 2013 from an overall net increase in revenue generating projects , primarily a result of our work on the u.s. special operations command 's talos project in 2014. gross profit overall , gross profit increased by approximately $ 1.0 million , or 166 % , as compared to the year ended december 31 , 2013. our medical device gross profit increased by $ 0.7 million , or 480 % , due to an increase of 52 units in the field . engineering services gross profit increased by $ 0.2 million , or 57 % , due primarily to a new revenue generating project with the u.s. special operations command . operating expenses sales and marketing expenses increased $ 2.8 million , or 65 % , as compared to the year ended december 31 , 2013 largely from an increase of $ 1.3 million in compensation related costs . in 2013 , compensation costs were kept low pending an inflow of investment capital . in addition , travel costs increased by $ 0.4 million , reflecting greater sales efforts , and stock compensation increased by $ 0.2 million , as a result of grants made during 2014. the fact that the company went public in early 2014 lead to a greater media presence during the year , which caused an increase in marketing related expenses by $ 0.6 million compared to 2013 . 49 research and development expenses increased $ 1.2 million , or 44 % , as compared to the year ended december 31 , 2013 primarily from an increase of $ 0.6 million in compensation related costs . as noted above , compensation costs were kept low in 2013 pending an inflow of investment capital . in addition , head count increased from approximately 13 employees at the end of 2013 to approximately 24 employees at the end of 2014. patent related expenses increased by approximately $ 0.2 million in 2014 compared to 2013. general and administrative expenses increased $ 3.5 million , or 89 % , as compared to the year ended december 31 , 2013 , due primarily to a $ 1.8 million increase in compensation-related costs as compared to the year ended december 31 , 2013. as noted above , compensation costs were kept low in 2013 pending an inflow of investment capital . in addition , we incurred $ 1.6 million in professional services fees primarily related to the merger , public company requirements and investor relations expenses . other income ( expense ) , net total other income ( expense ) , net reflected an increase of $

